Published in Curr Oncol Rep on May 01, 2002
Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer (2003) 3.44
A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights (2007) 2.39
Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer (2004) 2.39
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer (2010) 1.87
Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer (2005) 1.71
Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer (2006) 1.48
Pancreatic cancer cell-derived IGFBP-3 contributes to muscle wasting. J Exp Clin Cancer Res (2016) 1.41
Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer (2013) 1.25
Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res (2009) 1.25
The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer (2005) 1.24
Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer (2007) 1.21
Cancer cachexia--pathophysiology and management. J Gastroenterol (2013) 1.20
The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer (2004) 1.17
Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer (2013) 1.16
CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med (2009) 1.15
The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol (2006) 1.10
Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med (2012) 1.09
The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer (2006) 1.07
Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer. J Gastroenterol (2013) 1.04
C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS One (2015) 1.03
Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer (2004) 1.02
Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): implications of CRP and lipid peroxides. Cell Div (2009) 0.99
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol (2011) 0.99
Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol (2004) 0.95
Diminished quality of life in patients with cancer correlates with tryptophan degradation. J Cancer Res Clin Oncol (2007) 0.95
Biomarkers for cancer cachexia: is there also a genetic component to cachexia? Support Care Cancer (2007) 0.94
Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer. Br J Cancer (2010) 0.93
A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med (2014) 0.91
C-reactive protein as a prognostic factor for human osteosarcoma: a meta-analysis and literature review. PLoS One (2014) 0.91
C-reactive protein and risk of breast cancer: A systematic review and meta-analysis. Sci Rep (2015) 0.89
P-selectin genotype is associated with the development of cancer cachexia. EMBO Mol Med (2012) 0.89
A prospective study on C-reactive protein as a prognostic factor for survival time of terminally ill cancer patients. Support Care Cancer (2007) 0.87
Pre-treatment levels of C-reactive protein and squamous cell carcinoma antigen for predicting the aggressiveness of pharyngolaryngeal carcinoma. PLoS One (2013) 0.85
Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy--a longitudinal study. Br J Cancer (2005) 0.85
A prospective follow-up study of the relationship between C-reactive protein and human cancer risk in the Chinese Kailuan Female Cohort. Cancer Epidemiol Biomarkers Prev (2014) 0.85
Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE. Clin Mol Hepatol (2013) 0.84
The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapy. PLoS One (2013) 0.84
Using SCC antigen and CRP levels as prognostic biomarkers in recurrent oral cavity squamous cell carcinoma. PLoS One (2014) 0.84
New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. Clin Interv Aging (2008) 0.83
Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. Br J Cancer (2007) 0.83
Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies. Cancer Epidemiol Biomarkers Prev (2010) 0.82
Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma. Oncoimmunology (2015) 0.82
Melanoma biomarkers: Vox clamantis in deserto (Review). Oncol Lett (2010) 0.81
IL-1B -31T>C promoter polymorphism is associated with gastric stump cancer but not with early onset or conventional gastric cancers. Virchows Arch (2008) 0.81
Hyponatremia as an independent prognostic factor in patients with terminal cancer. Support Care Cancer (2014) 0.80
Systemic Inflammatory Response Based on Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker in Bladder Cancer. Dis Markers (2016) 0.79
Serum amyloid A, phospholipase A₂-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases. Inflamm Res (2013) 0.79
Modified glasgow prognostic score as a prognostic factor in gastriccancer patients: a systematic review and meta-analysis. Int J Clin Exp Med (2015) 0.78
Optimal indications of surgical palliation for incurable advanced gastric cancer presenting with malignant gastrointestinal obstruction. Gastric Cancer (2011) 0.78
Evaluation correlates C-reactive protein with advanced stage Hodgkin's lymphoma and response to treatment in a tertiary university hospital in Brazil. Rev Bras Hematol Hemoter (2015) 0.77
Glasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV. Med Arch (2014) 0.77
Serum markers of CYFRA 21-1 and C-reactive proteins in oral squamous cell carcinoma. World J Surg Oncol (2015) 0.77
Preoperative SCC Antigen, CRP Serum Levels, and Lymph Node Density in Oral Squamous Cell Carcinoma. Medicine (Baltimore) (2016) 0.76
Elevated Preoperative Serum Hs-CRP Level as a Prognostic Factor in Patients Who Underwent Resection for Hepatocellular Carcinoma. Medicine (Baltimore) (2015) 0.76
Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer patients with malignant pleural effusions. Yonsei Med J (2013) 0.76
Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies. World J Gastroenterol (2004) 0.75
Combination of telmisartan with cisplatin controls oral cancer cachexia in rats. Biomed Res Int (2013) 0.75
Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy. Medicine (Baltimore) (2017) 0.75
Renal Cell Carcinoma with Paraneoplastic Manifestations: Imaging with CT and F-18 FDG PET/CT. Radiol Case Rep (2015) 0.75
A systematically structured review of biomarkers of dying in cancer patients in the last months of life; An exploration of the biology of dying. PLoS One (2017) 0.75
Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis. PLoS One (2017) 0.75
Prognostic Value of the Combination of Preoperative Hemoglobin, Lymphocyte, Albumin, and Neutrophil in Patients with Locally Advanced Colorectal Cancer. Med Sci Monit (2016) 0.75
Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels. BMC Cancer (2016) 0.75
A New Preoperative Prognostic System Combining CRP and CA199 For Patients with Intrahepatic Cholangiocarcinoma. Clin Transl Gastroenterol (2017) 0.75
An interdisciplinary palliative rehabilitation intervention bolstering general self-efficacy to attenuate symptoms of depression in patients living with advanced cancer. Support Care Cancer (2015) 0.75
Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia. Support Care Cancer (2015) 0.75
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. Oncologist (2017) 0.75
Opioids, respiratory function, and dyspnea. Am J Hosp Palliat Care (2003) 0.85
Strategies for pain management: cleveland clinic foundation guidelines for opioid dosing for cancer pain. Support Cancer Ther (2004) 0.77
Opioids in cancer pain: common dosing errors. Oncology (Williston Park) (2003) 0.75
Adenosine triphosphate for cancer cachexia. Curr Oncol Rep (2002) 0.75